NCT02268136View on ClinicalTrials.gov

Increasing Dose Tolerance Study in Healthy Male Volunteers After Administration of BIII 890 CL

PHASE1TerminatedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

April 30, 1999

Primary Completion Date

December 31, 1999

Conditions
Healthy
Interventions
DRUG

BIII 890 CL

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY